SHX-005 is buccal film of racemic ketamine for treatment of major depressive disorders (MDD) and pain. The objective of SHX-005 is to develop a high drug-load and quick release dosage form for racemic ketamine based on SHX-001, by offering better pharmaceutical effect, rapid action time and more conveniency to carried on and dosed.
SHX-005 has demonstrated a long-term stability over 2 years. Additionally, Shenox has established a global intellectual proprietary system, having filled one PCT application and entered into publication status.
SHX-005 is very well positioned for development for ketamine using on pain management since it can be high loaded on the film matrix.